Short course immune induction therapy

EQS-News: Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need

Retrieved on: 
Monday, February 13, 2023
ET, Hepatology, Conference call, Conference, Internal medicine, DRS, Coeliac disease, Degenerative disease, Therapy, Mayo Clinic, Patient, Clinical trial, Disease, Division, Part, Research, Management, Dentistry, Pharmaceutical industry, Rheumatology, Webcast, Short course immune induction therapy, Gastroenterology

“We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.

Key Points: 
  • “We look forward to hosting this deep-dive discussion, focused on the current challenges of treating celiac disease with two, such renowned thought leaders as Drs.
  • Murray and Schumann,” stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update

Retrieved on: 
Thursday, October 27, 2022
U.S. Securities and Exchange Commission, Primary sclerosing cholangitis, DHODH, Private Securities Litigation Reform Act, Metabolism, Nature, Annual report, NEW, Degenerative disease, COVID-19, Clinical trial, Drug development, SEC, Risk, Security (finance), Psoriasis, Multiple sclerosis, Vaccine, Webcast, Short course immune induction therapy

NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2022, including a corporate update, on Thursday, November 3, 2022, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Key Points: 
  • To participate in the webcast, please register in advance at: https://imux.zoom.us/webinar/register/WN_g6raQxUTRQuuryWUU4Umig or on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic's website at: ir.imux.com/events-and-presentations .
  • IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction.

EQS-News: Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate

Retrieved on: 
Saturday, October 22, 2022
Psoriasis, U.S. Securities and Exchange Commission, SEC, Multiple sclerosis, Cytokine, Degenerative disease, Part, Antibody, Patient, Drug development, Primary sclerosing cholangitis, Security (finance), Nasdaq, Private Securities Litigation Reform Act, NEW, Serum, Psoriasis Area and Severity Index, PBMC, DHODH, Graft-versus-host disease, Nature, Safety, Clinical trial, Public expenditure, Inflammatory bowel disease, Metabolism, COVID-19, Human, Pharmaceutical industry, Vaccine, T helper 17 cell, Short course immune induction therapy

The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index (PASI) reductions in the two active arms did not separate from placebo at four weeks.

Key Points: 
  • The pre-planned interim analysis revealed that the group averages for Psoriasis Area and Severity Index (PASI) reductions in the two active arms did not separate from placebo at four weeks.
  • The primary objective was the evaluation of the safety and tolerability of IMU-935 in moderate-to-severe psoriasis patients.
  • The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period.
  • The unexpected high placebo rates observed in this interim analysis are disappointing and confound the evaluation of activity in the investigated active treatment arms.

EQS-News: Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022
Congress, UEG, Barrow Neurological Institute, Cleveland Clinic, Drug development, SEC, European Committee of the Regions, Nasdaq, Industry, Clinical trial, Private Securities Litigation Reform Act, ICDS, COVID-19, United European Gastroenterology, Biomarker, DHODH, U.S. Securities and Exchange Commission, Treatment, Psoriasis, Multiple sclerosis, Regeneration, Security (finance), Primary sclerosing cholangitis, NEW, Degenerative disease, Metabolism, Randomness, Research, Pharmaceutical industry, Short course immune induction therapy

The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .

Key Points: 
  • The poster presentation will be accessible on the Events and Presentations section of Immunic's website at: https://ir.imux.com/events-and-presentations .
  • Members of Immunics business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to managements and employees participation in scientific and industry conferences.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Immunic to Participate in Scientific and Industry Conferences in October

Retrieved on: 
Tuesday, October 4, 2022
Congress, UEG, Barrow Neurological Institute, Cleveland Clinic, Drug development, SEC, European Committee of the Regions, Risk, Industry, Clinical trial, Private Securities Litigation Reform Act, ICDS, COVID-19, Annual report, United European Gastroenterology, Biomarker, DHODH, U.S. Securities and Exchange Commission, Treatment, Psoriasis, Security (finance), Multiple sclerosis, Regeneration, Primary sclerosing cholangitis, Degenerative disease, Metabolism, Randomness, Research, Pharmaceutical industry, Vaccine, Short course immune induction therapy

Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.

Key Points: 
  • Members of Immunic's business development and investor relations teams will attend this conference in Leipzig, Germany and participate in partnering activities.
  • Examples of such statements include, but are not limited to, statements relating to management's and employee's participation in scientific and industry conferences.
  • Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
  • Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

TolerogenixX Publishes Three-Year Follow-Up Data from Phase I Trial of Immune Tolerance-Inducing MIC-Lx Cell Therapy

Retrieved on: 
Monday, September 26, 2022
Autoimmunity, Multiple sclerosis, Safety, Journal, Lupus, Short course immune induction therapy, Phenotype, Company, Society, Patient, Kidney transplantation, CEO, Technology, Immune tolerance, CTO, Cell, CSO, Clinical Journal of the American Society of Nephrology, Effectiveness, Degenerative disease, MIC, PD, Immune system, Leukapheresis, Immunosuppression, Transplant, Organ transplantation, Medical device, Dentistry, Vaccine

MIC cell treatment is a curative approach to achieve a sustained regulation of the immune system in transplant recipients and autoimmune patients.

Key Points: 
  • MIC cell treatment is a curative approach to achieve a sustained regulation of the immune system in transplant recipients and autoimmune patients.
  • Subsequently, the resulting cell therapy product called MIC-Lx is intravenously administered to the organ recipient prior to transplantation.
  • A multi-center Phase IIb trial codenamed TOL-2 enrolling 63 transplant couples consisting of a donor and a transplant recipient is underway.
  • MIC treatment is a personalized cell therapy approach modulating the immune system via a novel mode of action to achieve a specific and sustained immune tolerance.

EQS-News: Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects

Retrieved on: 
Tuesday, September 20, 2022
Pharmacokinetics, Half-life, Vital signs, Inflammation, Medication, Multiple sclerosis, Safety, ET, Irritable bowel syndrome, COVID-19, Disease, Physical examination, Inflammatory bowel disease, Diarrhea, Conditional sentence, Psoriasis, Daiichi Sankyo, NEW, Nature, Degenerative disease, Private Securities Litigation Reform Act, Metabolism, Regeneration, U.S. Securities and Exchange Commission, IMP, Patient, Clinical trial, Primary sclerosing cholangitis, Webcast, SAD, Nasdaq, MAD, Drug development, Security (finance), SEC, DHODH, AUC, Plasma, Proceedings of the Institution of Mechanical Engineers, Part C, Tolerability, Pharmaceutical industry, Vaccine, Dietary supplement, Online shopping, Single, Short course immune induction therapy, Part, Cmax, Tmax

Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.

Key Points: 
  • Single ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • These favorable results allowed a smooth transition to the MAD part of the trial.
  • Multiple ascending doses of IMU-856 were found to be safe and well-tolerated and no maximum tolerated dose was reached.
  • The unblinded data from the single and multiple ascending dose parts of our phase 1 clinical trial of IMU856 in healthy human subjects revealed a favorable safety, tolerability and pharmacokinetic profile.

Immuneering Announces Submission of IND Application to the FDA for Phase 1/2a Trial of IMM-1-104 to Treat Advanced Solid Tumors with RAS Mutations

Retrieved on: 
Friday, September 2, 2022
Cancer, Safety, Technology, Program, MAPK, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pancreatic cancer, Risk, Food, Colorectal cancer, Chemistry, China Bio-Immunity Corporation, NRAS, U.S. Securities and Exchange Commission, KRAS, GLOBE, FDA, Population, RAS, MEK, Neoplasm, Efficiency, Mutation, Drug discovery, Clinical trial, Growth, Forward-looking statement, Patient, Pharmaceutical industry, Medical imaging, Short course immune induction therapy, IND, Short course immune induction therapy

The IND application supports a Phase 1/2a clinical trial of IMM-1-104, an oral once daily small molecule in development for the treatment of advanced RAS mutant solid tumors.

Key Points: 
  • The IND application supports a Phase 1/2a clinical trial of IMM-1-104, an oral once daily small molecule in development for the treatment of advanced RAS mutant solid tumors.
  • At Immuneering we aim to create medicines for all patients with tumors driven by RAS mutations and other challenging MAPK pathway activation events.
  • In the interim, the company continues to prepare for the planned Phase 1/2a trial evaluating IMM-1-104 for the treatment of advanced solid tumors with RAS mutations.
  • IMM-1-104 is being developed to treat advanced solid tumors in patients harboring RAS mutations, and is translationally guided byImmuneering'sproprietary, human-aligned 3D tumor modeling platform combined with patient-aligned bioinformatics.

DGAP-News: Immunic, Inc. to Participate in Investor Conferences in September

Retrieved on: 
Thursday, September 1, 2022
Security (finance), COVID-19, Degenerative disease, Communication, DHODH, Risk, Multiple sclerosis, EDT, SEC, Psoriasis, U.S. Securities and Exchange Commission, NEW, Conference, Nasdaq, Primary sclerosing cholangitis, Wells, Wells Fargo, Clinical trial, Annual report, Private Securities Litigation Reform Act, Drug development, Metabolism, Pharmaceutical industry, Short course immune induction therapy

Dr. Vitt will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference in Boston on Friday, September 9, 2022 at 9:45 am EDT.

Key Points: 
  • Dr. Vitt will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference in Boston on Friday, September 9, 2022 at 9:45 am EDT.
  • A live webcast of the presentation will be available on the Events and Presentations section of Immunics website at: ir.imux.com/events-and-presentations .
  • An archived replay will be available on the companys website for a period of 90 days after the conference.
  • Examples of such statements include, but are not limited to, statements relating to managements participation in investor conferences.

Immunic, Inc. to Participate in Investor Conferences in September

Retrieved on: 
Thursday, September 1, 2022
Security (finance), COVID-19, Degenerative disease, Communication, DHODH, Risk, Multiple sclerosis, EDT, SEC, Psoriasis, U.S. Securities and Exchange Commission, Citigroup, Conference, Primary sclerosing cholangitis, Wells, Wells Fargo, Clinical trial, Annual report, Private Securities Litigation Reform Act, Drug development, Metabolism, Pharmaceutical industry, Short course immune induction therapy

Dr. Vitt will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference in Boston on Friday, September 9, 2022 at 9:45 am EDT.

Key Points: 
  • Dr. Vitt will participate in a fireside chat at the Wells Fargo 2022 Healthcare Conference in Boston on Friday, September 9, 2022 at 9:45 am EDT.
  • A live webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations .
  • An archived replay will be available on the company's website for a period of 90 days after the conference.
  • Examples of such statements include, but are not limited to, statements relating to management's participation in investor conferences.